Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer

Daniel F. Hayes, MD
Published: Wednesday, May 31, 2017



Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.

One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.

There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.
 


Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.

One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.

There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x